TDC
ICCC icon

Thompson Davis & Co’s ImmuCell ICCC Stock Holding History

Thompson Davis & Co’s Portfolio ICCC Stock Details ICCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-750
Closed -$3K – 828
2013
Q4 		$3K Buy
+750
New +$3.25K ﹤0.01% 622

Other funds holding ICCC

HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
SRC
Shufro Rose & Co New York $1.47B AUM 19.38% 1-Year Est. Return
SKK
Shepherd Kaplan Krochuk Boston, Massachusetts $119M AUM 8.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EFS
Essex Financial Services Essex, Connecticut $1.78B AUM 23.37% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
U
UBS Zurich, Switzerland $136B AUM 16.36% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Thompson Davis & Co's ICCC Position: Q1 2014 in Review

Thompson Davis & Co sold out of ImmuCell (ICCC) in Q1 2014, closing a stake of 750 shares — an estimated $3K sold.

Thompson Davis & Co first reported a position in ICCC in Q4 2013 and held it in 1 quarter. The position peaked at $3K in Q4 2013. 11 funds tracked by Wall St. Rank hold ICCC as of Q1 2014.

  • Thompson Davis & Co reported no remaining ImmuCell position as of Q1 2014 after selling out during the quarter.
  • Thompson Davis & Co sold 750 ImmuCell shares in Q1 2014, an estimated $3K.
  • Thompson Davis & Co first reported a position in ImmuCell in Q4 2013 and held it in 1 quarter.
  • Thompson Davis & Co's ImmuCell position peaked at $3K in Q4 2013.
  • 11 funds tracked by Wall St. Rank held ImmuCell as of Q1 2014.

Based on Thompson Davis & Co's 13F filing for Q1 2014, filed 9 May 2014.